In A Changing Diabetes Drug Market, Who Will Come Out On Top?
Executive Summary
New treatments for Type 2 diabetes are driving the optimism underlying Bristol and AstraZeneca’s proposed acquisition for Amylin and are leading to a re-alignment of allies and competitors focused on the disease. Companies are enthusiastic about the vast opportunity, yet worried about the costs and risks of full-scale commitment to it.
You may also be interested in...
Diabetes Is Not For The Faint Of Heart
Regulatory and commercial hurdles in the type 2 diabetes market have created a space where only the largest, most sophisticated companies can expect to compete.
Diabetes Is Not For The Faint Of Heart
Regulatory and commercial hurdles in the type 2 diabetes market have created a space where only the largest, most sophisticated companies can expect to compete.
Takeda’s Hat Trick Marks The First New Molecular Entity Of 2013
Takeda’s type 2 diabetes drug alogliptin – on its third pass through FDA – was cleared Jan. 25 as a single agent as Nesina, in combination with metformin as Kazano and in combination with pioglitazone as Oseni.